U.S. Pharmacist eNewsletter
October 2022

Pros and Cons of Pharmacy Compounding
There are significant differences between compounded drugs and FDA-approved drugs. For example, compounded drugs are not FDA approved, and therefore they are not reviewed by the FDA to evaluate their safety, effectiveness, or quality. On the other hand, compounded medications allow for customized, flexible, and precise dosing and are necessary when an FDA-approved drug product is not available or appropriate, or for which the usual strength or route of delivery must be altered. Read more.


Letter Urges Protecting Access to Compounded Hormones
The Alliance for Pharmacy Compounding recently reported that 1,957 prescribers of compounded hormones signed a letter  submitted to FDA Commissioner Robert Califf urging that he protect continued patient access to compounded hormone therapy. The signers also advocated expanded education on the use of bioidentical hormones for all healthcare practitioners. Read more.

Report Forecasts Expanding Compounding Pharmacies Market
Recent findings issued by Global Market Insights Inc., indicated that the compounding pharmacies market value is expected to reach 18.2 billion U.S. dollars by 2030. The report also indicated that the compounding pharmacies industry is projected to register a 5.5% compound annual growth rate between 2022 and 2030, adding that the sterile segment will record substantial growth. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App